New trial aims to ease cancer fatigue with common drug
NCT ID NCT07543536
First seen Apr 23, 2026 · Last updated Apr 29, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether megestrol acetate, given at the start of T-DXd treatment, can prevent or lessen fatigue in 132 women with advanced breast cancer. Fatigue is a common side effect of T-DXd, and the study measures changes in fatigue scores and quality of life. Participants are randomly assigned to receive either the drug or a placebo, without knowing which they get.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED, METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center
Guangzhou, Yuexiu District, 510060, China
Conditions
Explore the condition pages connected to this study.